Zydus Lifesciences — Fundamental View Q1 FY27 profit weak

🟢 Q1 FY27 Revenue: ~₹8,020 crore, +22% YoY EBITDA: ~₹1,930 crore; margin 24.1% PAT: ~₹940 crore, down ~36% YoY India branded formulations grew 20% International formulations grew 34% Consumer Wellness revenue grew 67%. The PAT decline therefore needs context: top-line growth remained strong, but profitability was affected by higher expenses/investments and the year-ago base. 🚀 Biggest future triggers 1. Saroglitazar — potentially the biggest catalyst: Zydus received USFDA Priority Review for Saroglitazar Magnesium for primary biliary cholangitis, with a US launch targeted for Q4 FY27. The company also reported positive Phase II(b) MASH data, with a 26.5% treatment difference on the primary endpoint. 2. US specialty transformation: Zydus launched Nufymco (ranibizumab), its first US biosimilar, and completed the acquisition of Assertio Holdings, strengthening its US specialty commercial platform. 3. Strong India business: Branded formulations grew 20%, with chronic/sub-chronic products reaching 54.2% of the portfolio, improving the quality and stability of the India business. 4. Buyback: The board approved a ₹1,100 crore buyback at ₹1,260/share, which provides some capital-return support to shareholders. 5. New product launches: Zydus received USFDA approval for Ascorbic Acid Injection with 180-day CGT exclusivity. The reference product had US sales of approximately $11.6 million, creating a near-term commercial opportunity.